[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity
Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported a transaction on 08/18/2025 selling 1,683 shares of the company's common stock. The filing states this was an issuer-mandated sale to satisfy tax withholding liabilities arising from the vesting and settlement of restricted stock units. The weighted-average proceeds reported were $18.238 per share (sales occurred at prices ranging from $18.00 to $18.50). After the sale, Mr. Allan beneficially owned 23,948 shares. The form is a routine Section 16 disclosure showing an internal tax-related disposition rather than a voluntary market-timed sale.
Jonathan Allan, General Counsel e Corporate Secretary di Stoke Therapeutics, Inc. (STOK), ha dichiarato una transazione il 18/08/2025 con la vendita di 1.683 azioni ordinarie della societ脿. La comunicazione indica che si 猫 trattato di una cessione imposta dall鈥檈mittente per soddisfare obblighi di ritenuta fiscale derivanti dal vesting e dal regolamento di unit脿 azionarie ristrette. I proventi medi ponderati sono stati $18.238 per azione (vendite effettuate a prezzi compresi tra $18.00 e $18.50). Dopo la vendita, il signor Allan possedeva beneficiariamente 23.948 azioni. Si tratta di un modulo di divulgazione di routine ai sensi della Sezione 16 che documenta una disposizione interna legata alle imposte e non una vendita volontaria programmata sul mercato.
Jonathan Allan, Asesor General y Secretario Corporativo de Stoke Therapeutics, Inc. (STOK), inform贸 una transacci贸n el 18/08/2025 en la que vendi贸 1.683 acciones ordinarias de la compa帽铆a. La presentaci贸n indica que fue una venta ordenada por el emisor para cubrir obligaciones de retenci贸n fiscal derivadas del vencimiento y liquidaci贸n de unidades de acciones restringidas. Los ingresos promedios ponderados reportados fueron de $18.238 por acci贸n (las ventas se realizaron en un rango de $18.00 a $18.50). Tras la venta, el se帽or Allan pose铆a beneficiosamente 23.948 acciones. El formulario es una divulgaci贸n rutinaria conforme a la Secci贸n 16 que refleja una disposici贸n interna por motivos fiscales y no una venta voluntaria cronometrada en el mercado.
Jonathan Allan, Stoke Therapeutics, Inc. (STOK)鞚� 氩曤瓿犽 瓴� 須岇偓靹滉赴, 電� 2025-08-18鞐� 須岇偓 氤错喌欤� 1,683欤茧ゼ 觳橂秳頃� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 鞚措姅 鞝滍暅欤�(RSU)鞚� 氩犾姢韺� 氚� 鞝曥偘鞙茧 氚滌儩頃� 鞗愳矞歆曥垬 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暅 氚滍枆靷� 歆�鞝� 毵る弰鞓�鞀惦媹雼�. 氤搓碃霅� 臧�欷戫弶攴� 靾橃澋鞚� 欤茧嫻 $18.238鞓�瓿�(瓯半灅臧�瓴� 氩旍渼電� $18.00~$18.50), 毵る弰 頉� Allan 鞌姅 23,948欤茧ゼ 鞁れ 靻岇湢頃橁碃 鞛堨棃鞀惦媹雼�. 鞚� 鞏戩嫕鞚� 鞁滌灔 韮�鞚措皪鞚� 雲鸽Π 鞛愲皽鞝� 毵る弰臧� 鞎勲媽 雮措秬 靹鸽 甏�霠� 觳橂秳鞚� 雮橅儉雮措姅 靹轨厴16鞚� 韱奠儊鞝� 瓿奠嫓鞛呺媹雼�.
Jonathan Allan, General Counsel et Secr茅taire G茅n茅ral de Stoke Therapeutics, Inc. (STOK), a d茅clar茅 une transaction le 18/08/2025 portant sur la vente de 1 683 actions ordinaires de la soci茅t茅. Le d茅p么t pr茅cise qu'il s'agissait d'une vente impos茅e par l'茅metteur pour r茅gler des obligations de retenue fiscale issues du vesting et du r猫glement d'unit茅s d'actions restreintes. Le produit moyen pond茅r茅 d茅clar茅 s'茅l猫ve 脿 18,238 $ par action (ventes r茅alis茅es 脿 des prix compris entre 18,00 $ et 18,50 $). Apr猫s la cession, M. Allan d茅tenait 脿 titre b茅n茅ficiaire 23 948 actions. Le formulaire constitue une divulgation routini猫re en vertu de la Section 16, montrant une disposition interne li茅e 脿 la fiscalit茅 plut么t qu'une vente volontaire visant le timing du march茅.
Jonathan Allan, General Counsel und Corporate Secretary von Stoke Therapeutics, Inc. (STOK), meldete am 18.08.2025 eine Transaktion, bei der er 1.683 Stammaktien des Unternehmens ver盲u脽erte. Die Einreichung gibt an, dass es sich um einen vom Emittenten veranlassten Verkauf zur Begleichung steuerlicher Abzugsverpflichtungen handelte, die aus dem Vesting und der Abwicklung von Restricted Stock Units resultierten. Der gemeldete gewogene Durchschnittserl枚s betrug $18.238 je Aktie (Verk盲ufe erfolgten zu Preisen zwischen $18.00 und $18.50). Nach dem Verkauf hielt Herr Allan wirtschaftlich 23.948 Aktien. Das Formular ist eine routinem盲脽ige Offenlegung nach Section 16 und dokumentiert eine interne steuerbedingte Verf眉gung, keine freiwillige markttimed Transaktion.
- Timely and clear disclosure of the insider transaction in accordance with Section 16 requirements
- Transaction explicitly described as issuer-mandated to satisfy tax withholding from RSU vesting, reducing ambiguity
- None.
Insights
TL;DR: Routine, compliance-driven insider sale to cover taxes; no new governance concerns evident.
This Form 4 documents a mandated sale to satisfy tax withholding on vested restricted stock units, a common administrative transaction. The reporting person is an officer and director, which makes transparency important; timely filing and clear explanation align with good governance practices. The transaction size (1,683 shares) and remaining beneficial ownership (23,948 shares) do not appear to indicate a change in insider control or a material shift in alignment with shareholders.
TL;DR: Administrative disposition with negligible market impact; disclosure is standard.
The sale was disclosed as issuer-mandated for tax withholding tied to RSU settlement and reported at a weighted-average price of $18.238, with trades ranging $18.00 to $18.50. The size of the sale relative to the reporter's post-transaction holdings suggests this was a mechanical tax-related event rather than a signal about company fundamentals. No derivative transactions or additional dispositions are reported.
Jonathan Allan, General Counsel e Corporate Secretary di Stoke Therapeutics, Inc. (STOK), ha dichiarato una transazione il 18/08/2025 con la vendita di 1.683 azioni ordinarie della societ脿. La comunicazione indica che si 猫 trattato di una cessione imposta dall鈥檈mittente per soddisfare obblighi di ritenuta fiscale derivanti dal vesting e dal regolamento di unit脿 azionarie ristrette. I proventi medi ponderati sono stati $18.238 per azione (vendite effettuate a prezzi compresi tra $18.00 e $18.50). Dopo la vendita, il signor Allan possedeva beneficiariamente 23.948 azioni. Si tratta di un modulo di divulgazione di routine ai sensi della Sezione 16 che documenta una disposizione interna legata alle imposte e non una vendita volontaria programmata sul mercato.
Jonathan Allan, Asesor General y Secretario Corporativo de Stoke Therapeutics, Inc. (STOK), inform贸 una transacci贸n el 18/08/2025 en la que vendi贸 1.683 acciones ordinarias de la compa帽铆a. La presentaci贸n indica que fue una venta ordenada por el emisor para cubrir obligaciones de retenci贸n fiscal derivadas del vencimiento y liquidaci贸n de unidades de acciones restringidas. Los ingresos promedios ponderados reportados fueron de $18.238 por acci贸n (las ventas se realizaron en un rango de $18.00 a $18.50). Tras la venta, el se帽or Allan pose铆a beneficiosamente 23.948 acciones. El formulario es una divulgaci贸n rutinaria conforme a la Secci贸n 16 que refleja una disposici贸n interna por motivos fiscales y no una venta voluntaria cronometrada en el mercado.
Jonathan Allan, Stoke Therapeutics, Inc. (STOK)鞚� 氩曤瓿犽 瓴� 須岇偓靹滉赴, 電� 2025-08-18鞐� 須岇偓 氤错喌欤� 1,683欤茧ゼ 觳橂秳頃� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 鞚措姅 鞝滍暅欤�(RSU)鞚� 氩犾姢韺� 氚� 鞝曥偘鞙茧 氚滌儩頃� 鞗愳矞歆曥垬 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暅 氚滍枆靷� 歆�鞝� 毵る弰鞓�鞀惦媹雼�. 氤搓碃霅� 臧�欷戫弶攴� 靾橃澋鞚� 欤茧嫻 $18.238鞓�瓿�(瓯半灅臧�瓴� 氩旍渼電� $18.00~$18.50), 毵る弰 頉� Allan 鞌姅 23,948欤茧ゼ 鞁れ 靻岇湢頃橁碃 鞛堨棃鞀惦媹雼�. 鞚� 鞏戩嫕鞚� 鞁滌灔 韮�鞚措皪鞚� 雲鸽Π 鞛愲皽鞝� 毵る弰臧� 鞎勲媽 雮措秬 靹鸽 甏�霠� 觳橂秳鞚� 雮橅儉雮措姅 靹轨厴16鞚� 韱奠儊鞝� 瓿奠嫓鞛呺媹雼�.
Jonathan Allan, General Counsel et Secr茅taire G茅n茅ral de Stoke Therapeutics, Inc. (STOK), a d茅clar茅 une transaction le 18/08/2025 portant sur la vente de 1 683 actions ordinaires de la soci茅t茅. Le d茅p么t pr茅cise qu'il s'agissait d'une vente impos茅e par l'茅metteur pour r茅gler des obligations de retenue fiscale issues du vesting et du r猫glement d'unit茅s d'actions restreintes. Le produit moyen pond茅r茅 d茅clar茅 s'茅l猫ve 脿 18,238 $ par action (ventes r茅alis茅es 脿 des prix compris entre 18,00 $ et 18,50 $). Apr猫s la cession, M. Allan d茅tenait 脿 titre b茅n茅ficiaire 23 948 actions. Le formulaire constitue une divulgation routini猫re en vertu de la Section 16, montrant une disposition interne li茅e 脿 la fiscalit茅 plut么t qu'une vente volontaire visant le timing du march茅.
Jonathan Allan, General Counsel und Corporate Secretary von Stoke Therapeutics, Inc. (STOK), meldete am 18.08.2025 eine Transaktion, bei der er 1.683 Stammaktien des Unternehmens ver盲u脽erte. Die Einreichung gibt an, dass es sich um einen vom Emittenten veranlassten Verkauf zur Begleichung steuerlicher Abzugsverpflichtungen handelte, die aus dem Vesting und der Abwicklung von Restricted Stock Units resultierten. Der gemeldete gewogene Durchschnittserl枚s betrug $18.238 je Aktie (Verk盲ufe erfolgten zu Preisen zwischen $18.00 und $18.50). Nach dem Verkauf hielt Herr Allan wirtschaftlich 23.948 Aktien. Das Formular ist eine routinem盲脽ige Offenlegung nach Section 16 und dokumentiert eine interne steuerbedingte Verf眉gung, keine freiwillige markttimed Transaktion.
FAQ
What did Jonathan Allan report on Form 4 for STOK?
At what price were the STOK shares sold in the Form 4 transaction?
How many STOK shares does Jonathan Allan own after the reported sale?
Why were the STOK shares sold according to the filing?
What is Jonathan Allan's role at Stoke Therapeutics (STOK)?
